Guide

The First Twelve Weeks on a GLP-1: What the Trials Actually Show

The first three months are titration, not results. The label directs 2.5 mg for four weeks before any increase, and adverse effects cluster in exactly this period — 4.3%

What this period is for

Reaching a dose you tolerate. That is the whole objective, and it is worth stating because almost every expectation people bring to the first twelve weeks is about the scale instead.

The tirzepatide label directs 2.5 mg once weekly for four weeks, then 5 mg, then increases in 2.5 mg increments no sooner than every four weeks based on tolerability and response. It states plainly that 2.5 mg is treatment initiation and is not approved as a maintenance dosage.

So at week twelve, following the label exactly, you would be at 7.5 mg at most — still below two of the three recommended maintenance dosages.

What the trial curve looks like here

SURMOUNT-1 ran 72 weeks and reported mean reductions of roughly 15.0%, 19.5% and 20.9% at 5, 10 and 15 mg. Those are endpoints. The curves rise steeply through the middle of the trial and flatten substantially in the second half.

Twelve weeks is early on that curve, at doses below the studied maintenance range. Comparing your week-twelve result to a 20.9% headline is comparing two different things.

What is common in this window

Gastrointestinal effects concentrated around dose increases rather than spread evenly. In SURMOUNT-1 at 15 mg: nausea in 29%, diarrhoea 23%, constipation 17%, vomiting 13%. Most were mild to moderate, and most clustered during escalation.

Reduced appetite and early fullness are the intended effect rather than a side effect, though they can shade into inadequate intake if unmanaged — which is one reason dietetic input is worth asking about.

Fatigue during escalation is frequently reported and generally settles.

The decision most people face around week eight

Whether to advance or hold. The label's four weeks is a minimum interval, not a schedule, and there is nothing requiring anyone to reach 15 mg — 5, 10 and 15 are all recommended maintenance dosages.

A programme that escalates on a fixed calendar without assessing tolerability is not following the label's logic. If side effects are difficult, holding at a lower dose is a legitimate clinical option and worth raising rather than enduring.

What to track, and why it beats the scale

1. Which day you inject and when effects appear relative to it.
2. Side effects by dose step — this is what tells your prescriber whether to advance.
3. Whether you are eating enough, not just less. Protein intake in particular.
4. Weight roughly weekly, same conditions, understanding that week-to-week noise exceeds signal.
5. Anything that made you consider stopping.

The costs that land in this window

Two things are worth knowing before week one rather than after.

Discontinuation risk is real. Roughly one in fourteen participants at the top dose in SURMOUNT-1 stopped because of an adverse event, and that happens during titration. If you prepaid twelve months for a lower rate, this is the period in which you find out whether that commitment was wise — which is the argument for the shorter prepaid term.

Price at the starting dose is not price at maintenance. If your programme charges more at higher doses, the bill rises through exactly this period. Ask what you pay at 10 mg before month one, not after.

When to contact your prescriber sooner

Severe abdominal pain, particularly radiating to the back. Vomiting that prevents keeping fluids down. Signs of an allergic reaction. Or anything that makes you consider stopping — because there are usually options between continuing as you are and stopping altogether.

Questions readers actually ask